Home > Archive > 2011 >

Volume 30, Number 1 (March/April)

Identification and Management of Charcot Neuroarthropathy (pages 6-10)

Georgeanne Botek, D.P.M, F.A.C.F.A.S., and Martha Anderson, D.P.M.

Diabetes is the most common cause of Charcot neuroarthropathy, an often-overlooked diabetic complication that can cause swelling, redness, pain, and structural damage in the foot. Drs. Botek and Anderson examine a typical case of Charcot foot and give a thorough review of its pathophysiology, diagnosis, and treatment. Radiographic images are included to show the different stages of the disease.
Complications and comorbiditiesFoot complications

The Role of Aspirin in the Prevention of Cardiovascular Events in Diabetes (pages 11-13)

Shailesh Nandish, M.D., and Robert Chilton, D.O., F.A.C.C.

The American Diabetes Association has released a new position statement on the use of aspirin for the prevention of cardiovascular disease (CVD) in patients with diabetes. Drs. Nandish and Chilton present an overview of the guidelines and discuss the role of increased platelet reactivity in CVD.
Complications and comorbiditiesCardiovascular disease

Renin-Angiotensin-Aldosterone System Blockers for Patients With Diabetes (pages 14-24)

Richa Gopal, M.D., M. James Lenhard, M.D., F.A.C.E., F.A.C.P., and Raelene E. Maser, Ph.D., M.T.(A.S.C.P.)

Drugs that block the renin-angiotensin-aldosterone system (RAAS) are mainstays of treatment for hypertension and nephropathy in diabetic patients. The authors examine the three types of RAAS blockers—angiotensin-converting enzyme inhibitors, angoiotensin II receptor blockers, and direct renin inhibitors—and compare their respective effects on cardiovascular disease and nephropathy, effects on mortality, side effects, and cost.
Drug treatmentAntihypertensives

Diabetes Care Recommendations—Then and Now (pages 25-26)

Charles A. Reasner, M.D.

As Practical Diabetology enters its thirtieth year, the Editor reflects on the changes in diabetes care that the last three decades have brought. A look back at the first ADA clinical practice recommendations reveals how much has changed in that time.
Professional guidelines

Insulin Pumps for Type 2 Diabetes—A Useful Tool? (pages 26-27)

Katherine Pereira, M.S.N., F.N.P.-B.C., A.D.M.-B.C.

Although insulin pumps have long been recommended for people with Type 1 diabetes, their use in people with Type 2 diabetes remains uncommon, and evidence for their benefit over injections remains controversial. Ms. Pereira reviews the evidence for the use of pumps in people with Type 2 diabetes and discusses the barriers to their use, which include the pumps’ high cost and patients’ need for education and support.
Drug treatmentInsulin
EquipmentInsulin pumps